Overview

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.
Details
Lead Sponsor:
Pfizer
Treatments:
Bazedoxifene
Diphosphonates
Raloxifene Hydrochloride